Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > New coverage out
View:
Post by simouuun on Oct 08, 2015 12:00pm

New coverage out

Just received this via newsletter lads:

TST.CN: Sleeper North of the Border with Priority Review; Initiating at Buy, 12-Mo.Price Target$1.50



[url=https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=html&co=Roth2&id=morningcallmin@roth.com&source=mail&pdfFileExtension=.pdf]https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=html&co=Roth2&id=morningcallmin@roth.com&source=mail&pdfFileExtension=.pdf[/url]
Comment by noinstinct89 on Oct 08, 2015 12:18pm
[url=https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=pdf&co=Roth2&id=morningcallmin@roth.com&source=mail]https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=pdf&co=Roth2&id=morningcallmin@roth.com&source=mail[/url]
Comment by 1wascallywabbit on Oct 08, 2015 12:19pm
TST.CN: Sleeper North of the Border with Priority Review; Initiating at Buy   We are initiating coverage of Telesta with a Buy rating and $1.50 price target. We believe Telesta has flown under the radar in Canada and the U.S. with a mixed company history. Fast forward to significantly streamlined operations, and importantly, Priority Review granted by the FDA for MCNA use in bladder ...more  
Comment by 1wascallywabbit on Oct 08, 2015 12:23pm
Note the Disclosures; (Bold is mine) Disclosures: Within the last twelve months, ROTH has received compensation for investment banking services from Telesta Therapeutics Inc. (OTC: BNHLF). ROTH makes a market in shares of Telesta Therapeutics Inc. (OTC: BNHLF) and Endo Pharmaceuticals Holdings and as such, buys and sells from customers on a principal basis
Comment by 1wascallywabbit on Oct 08, 2015 12:27pm
Better Link? https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=html&co=Roth2&id=morningcallmin@roth.com&source=mail&pdfFileExtension=.pdf
Comment by givmeabrake on Oct 08, 2015 12:18pm
Can you please re-post . That link seems encrypted.
Comment by BeenHereBefore on Oct 09, 2015 2:29am
That's not a link. Links do something when you click them. THIS is a link: [url=https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=pdf&co=Roth2&id=morningcallmin@roth.com&source=mail]https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=pdf&co=Roth2&id ...more  
Comment by BeenHereBefore on Oct 09, 2015 2:32am
Piece of shhit Stockhouse! https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb-b006b9503f82&mime=pdf&co=Roth2 BeenHereBefore wrote: That's not a link. Links do something when you click them. THIS is a link: [url=https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=6bfa69fa-faf3-435d-bfdb ...more  
Comment by givmeabrake on Oct 08, 2015 3:09pm
Price target $1.50  USD   HUGE!!! $1.95 CAD ehh!
Comment by 1wascallywabbit on Oct 08, 2015 6:21pm
Where do you see that the target is $1.50 USD. Everything else on the report is in cdn$, so why wouldn't the Target be the same?
Comment by HighteawithIntrepid on Oct 08, 2015 6:42pm
I think the $1.50 is a conservative NPV best guess so 1 year out the 1.50 could be a lot more because  they are factoring a discount for a possible no. I would think if we get an ADCOM yes the value would  increase enough to make their 1.50 CDN 1.50 US. HT
Comment by DamnYankees on Oct 08, 2015 6:47pm
the new analyst coverage was well received, trading red to end the day on Banhelef. the only people buying on the basement of the pinks are doing so on the way to or from their bookmaker. Let's  concede that no effort will be put into moving the share price and get the 15 for 1 outta the way. Oh, and I am happy to see that "failed to meet its end points" is becoming almost as ...more  
Comment by cheetio on Oct 08, 2015 8:20pm
The Saviours Reverse split Vision once the trading price of the Common Shares is greater than $1.50, the Common Shares will be eligible for margin lending by investment dealers in Canada.............1.50 hey target
Comment by DamnYankees on Oct 08, 2015 9:07pm
great Point Cheet. analyst report still implies huge risk. Just like the shelf financing held back the SP the supposed consolidation is doing the same. Most of them end badly, very badly. A positive  Adcomm won't do much of anything until the 15 for 1 is done and the Xmas option festival is out of the way. shareholders should have clued into theiR position on the totem pole by now but ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities